Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients

• Status: Completed
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if melatonin administration to end-of-life patients is effective in preventing the development of delirium compared with those who do not receive this treatment. Delirium is a difficult to control symptom commonly seen in patients at the end-of-life. A person who is delirious is unable to think clearly and cannot make sense of what is going on around him/her.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fraser Health
• Treatments: Melatonin

Criteria

Inclusion Criteria:

• Patients admitted to the test site

• Adult patients over 19 years of age

• Patients who can provide informed consent

• Patients who are able to tolerate oral medications

Exclusion Criteria:

• Patients with existing delirium or dementia on admission

• Patients with poor clinical performance

• Patients taking melatonin prior to admission

• Patients taking medications that interact with melatonin

• Patients who are unable to provide informed consent

• Patients who are enrolled in any other research study involving drugs/devices